Physician profile
Robert Schulze
NPI 1841299427
$4,196.61
in general payments reported to CMS, 2019-2025
26 companies · $58.07 in 2025
The $58.07 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $807 · 2020: $29.05 · 2022: $444 · 2023: $1,218 · 2024: $1,641 · 2025: $58.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,917.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,917.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $793.11 | 2019-2024 | |
| Amgen INC. | $629.07 | 2019-2024 | Repatha |
| Pfizer INC. | $451.06 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $267.58 | 2019-2024 | Eliquis, Camzyos |
| Boston Scientific Corporation | $204.95 | 2019-2024 | |
| Atricure, INC. | $193.39 | 2024-2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Medtronic, INC. | $189.38 | 2022-2024 | Micra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.51 | 2022-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $163.99 | 2019-2024 | Xarelto |
| Abbott Laboratories | $154.39 | 2019-2024 | Jot Dx, Thoratec Heartmate 3 Lvas Implant Kit |
| Merck Sharp & Dohme LLC | $147.47 | 2022-2023 | Verquvo |
| Alnylam Pharmaceuticals INC. | $130.45 | 2022-2024 | Onpattro |
| Esperion Therapeutics, INC. | $95.51 | 2022-2024 | Nexletol |
| Scpharmaceuticals INC. | $81.87 | 2023-2024 | |
| Kiniksa Pharmaceuticals International, Plc | $81.36 | 2024 | Arcalyst |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $79.87 | 2019-2024 | Wainua, Brilinta |
| Novo Nordisk INC | $75.98 | 2024 | Wegovy, Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $67.55 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $56.34 | 2023-2024 | Opsumit, Uptravi |
| Lexicon Pharmaceuticals, INC. | $42.50 | 2023 | Inpefa |
| Kiniksa Pharmaceuticals, LTD. | $39.25 | 2022-2023 | Arcalyst |
| Impulse Dynamics (USA) INC. | $26.79 | 2023 | Optimizer |
| Regeneron Healthcare Solutions, INC. | $18.98 | 2023 | Praluent, Evkeeza |
| Bayer Healthcare Pharmaceuticals INC. | $15.85 | 2024 | |
| Edwards Lifesciences Corporation | $12.99 | 2023 | Sapien 3 Ultra Resilia |
| Cvrx, INC. | $11.42 | 2024 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Schulze listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.